LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

Home・Stock List・Alkermes PLC

Alkermes PLC

Open

Sector Healthcare

26.36 1.93

Buy Sell

Overview

Share price change

24h

Current

Min

26.08

Max

26.82

Key metrics
By Trading Economics
Income	55M 91M
Sales	49M 399M
P/E Sector Avg	7.17 112.16
EPS	0.72
Profit margin	22.891
EBITDA	68M 129M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+31.55 upside

Market Stats
By TradingEconomics
Market Cap	-139M 4.7B
Previous open	24.43
Previous close	26.36

News Sentiment

By Acuity

50%

190 / 389 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

26.01 / 28.09 Support & Resistance

Alkermes PLC Chart

Past performance is not a reliable indicator of future results.

Related News

14 Dec 2023, 11:06 UTC

Acquisitions, Mergers, Takeovers

Alkermes Athlone Facility Has About 400 Employees >ALKS

14 Dec 2023, 11:06 UTC

Acquisitions, Mergers, Takeovers

Alkermes to Get Cash Payment of $92.5 Million for Facility, Related Assets >ALKS

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

31.55% upside

12 Months Forecast

Average 34.9 USD 31.55%

High 50 USD

Low 25 USD

Based on 12 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Alkermes PLC - Dist in the past 3 months.

Technical Score

By Trading Central

26.01 / 28.09Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

190 / 389 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.